IN8bio, Inc. (INAB) stock
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.82+0.00 (+0.49%)
Close on Nov 17, 2026Market cap $8.08MP/E –Yield –
IN8bio cash
Cash and short-term investments held at the end of each period.
IN8bio's cash was $17.96M at Jun 30, 2026. For fiscal 2025 it was $27.09M, up 137.9% from the year before. The highest annual figure on record is $37.27M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.09M | +137.9% |
| FY2024 | Dec 31, 2024 | $11.39M | -47.1% |
| FY2023 | Dec 31, 2023 | $21.54M | +16.8% |
| FY2022 | Dec 31, 2022 | $18.43M | -50.5% |
| FY2021 | Dec 31, 2021 | $37.27M | +105.5% |
| FY2020 | Dec 31, 2020 | $18.14M | +2314.8% |
| FY2019 | Dec 31, 2019 | $751.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.96M | +35.8% |
| Q1 FY2026 | Mar 31, 2026 | $21.94M | +84.6% |
| Q4 FY2025 | Dec 31, 2025 | $27.09M | +137.9% |
| Q3 FY2025 | Sep 30, 2025 | $10.69M | +167.2% |
| Q2 FY2025 | Jun 30, 2025 | $13.23M | +29.5% |
| Q1 FY2025 | Mar 31, 2025 | $11.89M | -8.7% |
| Q4 FY2024 | Dec 31, 2024 | $11.39M | -47.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.00M | -68.9% |
| Q2 FY2024 | Jun 30, 2024 | $10.22M | -39.9% |
| Q1 FY2024 | Mar 31, 2024 | $13.02M | +19.8% |
| Q4 FY2023 | Dec 31, 2023 | $21.54M | +16.8% |
| Q3 FY2023 | Sep 30, 2023 | $12.85M | -53.5% |
| Q2 FY2023 | Jun 30, 2023 | $16.99M | -34.0% |
| Q1 FY2023 | Mar 31, 2023 | $10.86M | -66.2% |
| Q4 FY2022 | Dec 31, 2022 | $18.43M | -50.5% |
| Q3 FY2022 | Sep 30, 2022 | $27.65M | -31.6% |
| Q2 FY2022 | Jun 30, 2022 | $25.74M | +114.5% |
| Q1 FY2022 | Mar 31, 2022 | $32.11M | +113.3% |
| Q4 FY2021 | Dec 31, 2021 | $37.27M | +105.5% |
| Q3 FY2021 | Sep 30, 2021 | $40.42M | +95.6% |
| Q2 FY2021 | Jun 30, 2021 | $12.00M | +277.3% |
| Q1 FY2021 | Mar 31, 2021 | $15.05M | +1904.3% |
| Q4 FY2020 | Dec 31, 2020 | $18.14M | – |
| Q3 FY2020 | Sep 30, 2020 | $20.67M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.18M | – |
| Q4 FY2019 | Dec 31, 2019 | $751.00K | – |
See a number that looks wrong?